Bronchodilatory and anti-inflammatory effects of ASM-024, a nicotinic receptor ligand, developed for the treatment of asthma

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Assayag, Evelyne Israël ^a,b   Beaulieu, Marie Josée ^a   Cormier, Yvon ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b Asmacure Ltée   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ASM 024; UNCLASSIFIED DRUG;

AEROSOL; ALLERGIC AIRWAY INFLAMMATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; BRONCHUS HYPERREACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG MECHANISM; GUINEA PIG; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG LAVAGE; MOUSE; NONHUMAN; PROPHYLAXIS; SMOOTH MUSCLE RELAXATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ALLERGENS; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; AZEPINES; BRONCHODILATOR AGENTS; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HUMANS; LIGANDS; MICE; MUSCLE, SMOOTH; RECEPTORS, NICOTINIC; RESPIRATORY HYPERSENSITIVITY; TRACHEA;

EID: 84899878169     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086091     Document Type: Article

References (35)

1. World Health Organization (2008) Asthma fact sheet No. 307. Updated November 2013. Available: http://www.who.int/mediacentre/factsheets/fs307/en/ index.html. Accessed 2013 Dec 31.
2. Global Initiative for Asthma (GINA) (2011) Global Strategy for Asthma Management and Prevention. Available: http://www.ginasthma.org/. Accessed 2013 Dec31.
3. Bousquet J, Bachert C, Canonica GW, Casale TB, Cruz AA, et al. (2009) Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin. Immunol 124: 428-433.
4. Yates DH, Worsdell M, Barnes PJ (1997) Effect of regular salmeterol treatment on albuterol-induced bronchoprotection in mild asthma. Am J Respir Crit Care Med 156: 988-991. (Pubitemid 27396445)
5. Sears MR (2002) Adverse effects of b-agonists. J Allergy Clin Immunol 110: S322-328.
6. Barnes PJ, Adcock IM (2009) Glucocorticoid resistance in inflammatory diseases. Lancet 373 (9678):1905-1917.
7. O'Byrne PM, Naji N, Gauvreau GM (2012) Severe asthma: future treatments. Clinical & Experimental Allergy 42 (5): 706-711.
8. Kupczyk M, Wenzel S (2012) U.S. and European severe asthma cohorts: what can they teach us about severe asthma? J Intern Med 272 (2):121-32.
9. Durham A, Adcock IM, Tliba O (2011) Steroid resistance in severe asthma: current mechanisms and future treatments. Curr Pharm Des 17 (7) 674-684.
10. Pieper MP (2012) The non-neuronal cholinergic system as novel drug target in the airways. Life Sci 91(21-22):1113-1118.
11. Pavlov VA (2008) Cholinergic modulation of inflammation. Int J Clin Exp Med 1:203-212.
12. Gwilt CR, Donnelly LE, Rogers DF (2007) The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol Ther 115:208-222. (Pubitemid 47042914)
13. Wang H, Yu M, Ochani M (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 42:384-388. (Pubitemid 36157937)
14. Hurst R, Rollema H, Bertrand D (2013) Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther 137(1):22-54.
15. Karakiulakis G, Roth M (2012) Muscarinic Receptors and Their Antagonists in COPD: Anti-Inflammatory and Anti-remodeling Effects. Mediators Inflamm 2012:409580.
16. Troisi RJ, Speizer FE, Rosner B, Trichopoulos D, Willett WC (1995) Cigarette smoking and incidence of chronic bronchitis and asthma in women. Chest 108:1557-1561.
17. Godtfredsen NS, Lange P, Prescott E, Osler M, Vestbo J (2001) Changes in smoking habits and risk of asthma: a longitudinal population based study. Eur Respir J 18:549-554. (Pubitemid 32895642)
18. Sopori M (2002) Effects of cigarette smoke on the immune system. Nat Rev Immunol 2(5):372-377.
19. Floto RA, Smith KG (2003) The vagus nerve, macrophages, and nicotine. Lancet 361 (9363):1069-1070. (Pubitemid 36369556)
20. Blanchet MR, Israël-Assayag E, Cormier Y (2005) Modulation of airway inflammation and resistance in mice by a nicotinic receptor agonist. Eur Respir J 26:21-27.
21. Dorion G, Israël-Assayag E, Beaulieu MJ, Cormier Y (2005) Effect of 1,1-dimethylphenyl 1,4-piperazinium on mouse tracheal smooth muscle responsiveness. Am J Physiol Lung Cell Mol Physiol 288(6):L1139-45.
22. Blanchet MR, Langlois A, Israël-Assayag E, Beaulieu MJ, Ferland C, et al. (2007) Modulation of eosinophil activation in vitro by a nicotinic receptor agonist. J Leukoc Biol 81:1245-1251.
23. Stokes C, Israël-Assayag E, Papke RL (2013) A minimal pharmacophore for a nicotinic alpha7 silent agonist, relevance for the therapeutic development of treatments for asthma. Abstract presented at the Society for Neuroscience, November, San-Diego.
24. Chojnacka K, Papke RL, Horenstein NA (2013) Synthesis and evaluation of a conditionally-silent agonist for the a7 nicotinic acetylcholine receptor. Bioorganic and Medicinal Chemistry Letters; 23 4145-4149.
25. Kolahian S, Gosens R (2012) Cholinergic regulation of airway inflammation and remodelling. J Allergy (Cairo) 2012:681258.
26. Hosur V, Loring RH (2011) α4b2 nicotinic receptors partially mediate anti-inflammatory effects through Janus kinase 2-signal transducer and activator of transcription 3 but not calcium or cAMP signaling. Mol Pharmacol 79(1):167-74.
27. Mikulski Z, Hartmann P, Jositsch G, Zasłona Z, et al. (2010) Nicotinic receptors on rat alveolar macrophages dampen ATP-induced increase in cytosolic calcium concentration. Respiratory Research 11:133.
28. Simard AR, Gan Y, St-Pierre S, Kousari A, Patel V, et al. (2013) Differential modulation of EAE by α9*- and β2*- nicotinic acetylcholine receptors. Immunology and Cell Biology 91(3):195-200.
29. Kistemaker LE, Oenema TA, Meurs H, Gosens R (2012) Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci 91(21-22):1126-1133.
30. Wessler I, Kirkpatrick CJ (2008) Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. British Journal of Pharmacology 154, 1558-1571.
31. Suzuki T, Hide I, Matsubara A, Hama C, Harada K, et al. (2006) Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J Neurosci Res 83(8):1461-1470. (Pubitemid 43844991)
32. de Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, et al. (2005) Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 6(8):844-851. (Pubitemid 43090471)
33. Marrero MB, Bencherif M (2009) Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB. Brain Res 1256:1-7.
34. Buccafusco JJ, Beach JW, Terry AV Jr (2009) Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 328(2):364-70.
35. Israël-Assayag E, Vachon L, Aubin S, Cormier Y (2010) Targeting Nicotinic Acetylcholine Receptors To Treat Asthma: Pharmacokinetics And Metabolism Of ASM-024, A New Nicotinic Receptor Agonist AJRCCM conference.181.1 Meeting Abstracts.A5398.